The objective of the research described in the present article was to estimate the costs of hepatitis C virus (HCV), hepatitis B virus (HBV) and human immunodeficiency virus (HIV) infection by intravenous drug use in countries of the European Union.
The pharmaco-economic model applied linked incidence to lifetime cost estimates (incidence-based model). Estimates are presented within a broader framework of social costs.
In the baseline, estimated costs of HCV, HBV and HIV infection related to drug addiction amount to 1.89 euros ( € ). In sensitivity analysis, costs up to € 2.57 are estimated (0.5 per cent of total European Union expenditures on health care).
A preliminary estimate for the costs of HCV, HBV and HIV infection related to drug addiction in the European Union is provided. Those costs reflect a relevant share of total costs related to drug addiction.
© 2001-2024 Fundación Dialnet · Todos los derechos reservados